7,983 reports of this reaction
2.8% of all NATALIZUMAB reports
#7 most reported adverse reaction
ASTHENIA is the #7 most commonly reported adverse reaction for NATALIZUMAB, manufactured by Biogen Inc.. There are 7,983 FDA adverse event reports linking NATALIZUMAB to ASTHENIA. This represents approximately 2.8% of all 289,050 adverse event reports for this drug.
NATALIZUMAB has an overall safety score of 75 out of 100. Patients taking NATALIZUMAB who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for NATALIZUMAB, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for NATALIZUMAB:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 7,983 FDA reports for NATALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 2.8% of all adverse event reports for NATALIZUMAB, making it a notable side effect.
If you experience asthenia while taking NATALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.